-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The clinical symptoms of people infected with severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) are extensive, including cough, fever, discomfort, myocarditis and gastrointestinal symptoms, and can progress to acute respiratory distress syndrome in severe patients.
currently known risk factors for severe illness include men, seniority, cardiovascular disease, lung disease, hypertension, diabetes or obesity, while mild patients with high risk factors can progress to severe illness in a shorter period of time.
antibody Bamlanivimab to obtain FDA Emergency Use Authorization (EUA) for the treatment of moderate to severe COVID-19 adult patients and preventive treatment in critically at-risk populations.
researchers recently compared the treatment effects of Bamlanivimab single-drug or in association with medium-to-moderate anti-Etesevimab for patients with mild and moderate neo-coronary pneumonia.
BLAZE-1 study was a Phase II-III clinical study conducted at 49 medical centers in the United States, involving 613 patients who tested positive for neo-coronary pneumonia and were assessed as mild and moderate in clinical symptoms.
patients were treated with Bamlanivimab monotherapy or placebo between 17 June and 21 August 2020, followed by Bamlanivimab monotherapy or Bamlanivimab-Etesimaevb, of which 101 patients received a single 700mg Bamlanivima b treatment, 107 patients received 2800 mg Bamlanivimab treatment, 101 patients received 7,000 mg Bamlanivimab treatment, 112 patients received 2800 mg Bamlanivimab combined 2800 mg Etesevimab, 156 patients received placebo.
end of the study was the change in the log value of the virus load on the 11th day.
44.7 years of age, 54.6 percent of women and 92.4 percent of patients completed the study.
11th day of the 700mg Bamlanivimab treatment group, the viral load Log value decreased by 3.72,2800mg compared to the baseline, while the 7000mg group decreased by 3.49, and the Bamlanivimab-Etesevimab's combined treatment group decreased by 4.37, while the placebo group decreased by 3.80, and the virus load Log values of each group decreased by 0.09, -0.27, 0.31 and -0.57, respectively, compared to the placebo.
10 of the 84 secondary endpoints were statistically significant, including the hospitalization and emergency rates for neo-crown pneumonia: 5.8 per cent in the placebo group and 1.0 in the 700mg Bamlanivimab treatment group 1.9 per cent in the 2800mg Bamlanivimab group, 2.0 per cent in the 7000mg Bamlanivimab group and 0.9 per cent in the Bamlanivb-Etesevimab combined treatment group.
allergic reaction immediately after treatment in nine patients, including 1 in the placebo group.
did not occur during the study period.
study found that for patients with mild and moderate symptoms of new coronary pneumonia who did not need to be hospitalized, the combination therapy of the nemetic antibody bamlanivimab-etesevimab significantly reduced viral load, while bamlanivimab monotherapy had no significant effect on viral load.